Blood Pressure Control May Help Mitigate Dementia Risk From Hypertension
Researchers sought to assess the age at which the population attributable fraction of dementia from hypertension would be the highest.
Diagnosis & Disease Information
Limited Drug Exposure Data Halt Accelerated Approval Attempt for Donanemab
Donanemab is an antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
Why Women May Have a Higher Risk of Developing Dementia Than Men
In an international meta-analysis, researchers evaluated sex differences in all-cause dementia risk across diverse ethno-regional groups.
Hormone Replacement Therapy as a Potential Alzheimer Disease Preventive Strategy
Researchers sought to assess the role of APOE genotype and age at HRT initiation on the heterogeneity in cognitive response to HRT.
Aducanumab, Lecanemab for Early AD: The Clinical Trials That Led to FDA Approval
These are the clinical trials that led to the FDA’s approval of aducanumab and lecanemab for early AD, plus, the concerns that loom.
Brexpiprazole Gets Priority Review for Agitation With Alzheimer Dementia
The sNDA is supported by data from two phase 3 studies that evaluated the efficacy and safety of brexpiprazole in patients with agitation associated with Alzheimer dementia.
Education May Predict Dementia Risk Among Centenarians and Near-Centenarians
In a meta-analysis, researchers estimated the prevalence of dementia in a centenarian and near-centenarian population and identified the risk and protective factors for dementia.
Vitamin D Levels in the Brain Correlate With Dementia Risk in Older Adults
Researchers sought to analyze brain concentrations of vitamin D and assess whether there were any associations with cognitive and neuropathology outcomes.
Vitamin D Deficiency Linked to Neurologic Disorders
Research findings support the use of vitamin D supplementation to help slow cognitive decline in Alzheimer dementia and reduce Parkinson disease symptom severity.
Gantenerumab Fails to Meet Endpoints in Early Alzheimer Disease Trials
Gantenerumab is an investigational immunoglobulin G1 antibody designed to increase the clearance of soluble amyloid beta from the brain.
- Loading...
Loading...
Next post in Neurology
Loading... 
Loading...